Salvage focal brachytherapy in castration-resistant prostate cancer with neuroendocrine differentiation after radiation therapy

Takahiro Komori, Takeo Kosaka, Keitaro Watanabe, Tomoki Tanaka, Yota Yasumizu, Hiroshi Hongo, Shuji Mikami, Toshio Ohashi, Mototsugu Oya

Research output: Contribution to journalArticlepeer-review

Abstract

Introduction: Treatment strategy for castration-resistant prostate cancer with neuroendocrine differentiation after radiation therapy has not been established. Case presentation: We described a case of castration-resistant prostate cancer with neuroendocrine differentiation after initial external beam radiotherapy followed by salvage androgen deprivation therapy. Magnetic resonance imaging detected recurrence of a suspicious lesion in the left lobe of the prostate, although the prostate-specific antigen level was <0.2 ng/mL. Transperineal prostate saturation needle biopsy detected adenocarcinoma with neuroendocrine differentiation. The patient underwent salvage focal brachytherapy and had a prostate-specific antigen progression-free survival of 20 months with no obvious adverse events. No recurrence has been detected on magnetic resonance imaging for 18 months. Conclusion: Salvage focal brachytherapy for prostate cancer after external beam radiotherapy can be one of the treatment strategies for local recurrence of castration-resistant prostate cancer with neuroendocrine differentiation.

Original languageEnglish
Pages (from-to)233-236
Number of pages4
JournalIJU Case Reports
Volume5
Issue number4
DOIs
Publication statusPublished - 2022 Jul

Keywords

  • castration-resistant prostate cancer (CRPC) with neuroendocrine differentiation
  • prostate cancer
  • salvage focal brachytherapy

ASJC Scopus subject areas

  • Urology

Fingerprint

Dive into the research topics of 'Salvage focal brachytherapy in castration-resistant prostate cancer with neuroendocrine differentiation after radiation therapy'. Together they form a unique fingerprint.

Cite this